ARCHIVES

Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says

This article is from The Cancer Letter archive.

Vol. 22 No. 17 | April 26, 1996

Download PDF Visit The Full Archive

Related Articles

Cancer Center Lineup complete: 11 Renewals, Funding Continued for Three, Two Unfunded

September 28, 1990

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

Acceptance Of Sentinel Node Biopsy Is Growing, Study Finds

October 31, 2003

Clinical Oncology Study Section In Draft; ET2 May Be Eliminated, NIH Official Says

February 13, 1998

Immunobiology Ready For Grants; Terry Says; Centers Job Permanent

January 27, 1978

Scientists Lose Credibility When “Fire Alarm” Pulled Too Early, ACS’s Brawley Says.

August 1, 2008